BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pivot XB, Li RK, Thomas ES, Chung HC, Fein LE, Chan VF, Jassem J, de Mendoza FH, Mukhopadyay P, Roché HH. Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. Eur J Cancer. 2009;45:2940-2946. [PMID: 19683429 DOI: 10.1016/j.ejca.2009.07.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34:2460-2467. [PMID: 27138582 DOI: 10.1200/jco.2015.64.8931] [Cited by in Crossref: 707] [Cited by in F6Publishing: 406] [Article Influence: 141.4] [Reference Citation Analysis]
2 Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009;20:1913-1927. [PMID: 19901010 DOI: 10.1093/annonc/mdp492] [Cited by in Crossref: 357] [Cited by in F6Publishing: 326] [Article Influence: 29.8] [Reference Citation Analysis]
3 Hwang KA, Park MA, Kang NH, Yi BR, Hyun SH, Jeung EB, Choi KC. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways. Toxicol Appl Pharmacol 2013;272:637-46. [PMID: 23933164 DOI: 10.1016/j.taap.2013.07.027] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
4 Denduluri N, Swain S. Ixabepilone: Clinical Role in Metastatic Breast Cancer. Clinical Breast Cancer 2011;11:139-45. [DOI: 10.1016/j.clbc.2011.03.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
5 Trédan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J, Hardy-Bessard AC, Arance A, Mukhopadhyay P, Aloe A, Roché H. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. Clin Breast Cancer 2015;15:8-15. [PMID: 25218708 DOI: 10.1016/j.clbc.2014.07.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
6 Campone M, Lacroix-Triki M, Roca L, Spielmann M, Wildiers H, Cottu P, Kerbrat P, Levy C, Desmoulins I, Bachelot T, Winston T, Eymard JC, Uwer L, Duhoux FP, Verhoeven D, Jaubert D, Coeffic D, Orfeuvre H, Canon JL, Asselain B, Martin AL, Lemonnier J, Roché H. UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. Eur J Cancer 2018;103:184-94. [PMID: 30267987 DOI: 10.1016/j.ejca.2018.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nanda R. “Targeting” Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers. Seminars in Oncology 2011;38:254-62. [DOI: 10.1053/j.seminoncol.2011.01.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
8 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
9 Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010;70:2247-58. [PMID: 21080741 DOI: 10.2165/11538150-000000000-00000] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
10 Li CH, Karantza V, Aktan G, Lala M. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res. 2019;21:143. [PMID: 31842957 DOI: 10.1186/s13058-019-1210-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
11 Rubovszky G, Udvarhelyi N, Horváth Z, Láng I, Kásler M. A tripla-negatív emlőkarcinóma – irodalmi áttekintés. Magyar Onkológia 2010;54:325-35. [DOI: 10.1556/monkol.54.2010.4.6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Awada A, Garcia AA, Chan S, Jerusalem GHM, Coleman RE, Huizing MT, Mehdi A, O'reilly SM, Hamm JT, Barrett-lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. The Lancet Oncology 2013;14:1216-25. [DOI: 10.1016/s1470-2045(13)70429-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
13 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 47.7] [Reference Citation Analysis]
14 Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16 Suppl 1:1-11. [PMID: 21278435 DOI: 10.1634/theoncologist.2011-s1-01] [Cited by in Crossref: 448] [Cited by in F6Publishing: 278] [Article Influence: 44.8] [Reference Citation Analysis]
15 Kontani K, Hashimoto SI, Murazawa C, Norimura S, Tanaka H, Ohtani M, Fujiwara-Honjo N, Date M, Houchi H, Yokomise H. Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol Clin Oncol. 2013;1:225-230. [PMID: 24649151 DOI: 10.3892/mco.2012.49] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
16 Kaklamani VG, Xu BH, Gomez HL. Global experience with ixabepilone in breast cancer. Expert Rev Anticancer Ther 2011;11:683-92. [PMID: 21554041 DOI: 10.1586/era.11.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Mccarthy N, Mitchell G, Bilous M, Wilcken N, Lindeman GJ. Triple-negative breast cancer: making the most of a misnomer: TNBC: classification and management. Asia-Pacific Journal of Clinical Oncology 2012;8:145-55. [DOI: 10.1111/j.1743-7563.2012.01533.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]